SVA merger forms BetaNova to pursue type 1 diabetes cure
BetaNova Biotherapeutics is formed from a merger, combining proprietary cell therapy, gene-editing and implantable device technologies to target a functional cure for type 1 diabetes.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.